IQVIA Holdings Inc.
IQV
$173.26
+0.50%
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the healthcare industry. It is a leading player formed from the merger of Quintiles and IMS Health, uniquely combining data analytics with contract research capabilities.…
IQV
IQVIA Holdings Inc.
$173.26
Investment Opinion: Should I buy IQV Today?
Based on a synthesis of the data, the objective assessment is a Hold. The company's strong underlying business metrics, including double-digit revenue growth, robust cash flow, and high ROE, are compelling. However, these are counterbalanced by significant balance sheet risks, poor recent technical performance, and a valuation that is not compelling enough to warrant a new Buy rating at this time. Investors should await stabilization in the share price and/or an improvement in the debt profile before considering an increased position.
Sign up to view all
IQV 12-Month Price Forecast
The outlook is balanced with a tilt towards cautious optimism. The fundamental business is healthy, but the stock needs to navigate significant headwinds related to its balance sheet and regaining market trust. The base case of a gradual recovery is most probable.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IQVIA Holdings Inc.'s 12-month outlook, with a consensus price target around $225.24 and implied upside of +30.0% versus the current price.
Average Target
$225.24
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$139 - $225
Analyst target range
Wall Street analyst coverage for IQVIA is active, with 13 analysts providing estimates. The consensus estimates for future performance include an average EPS of $19.50 and average revenue of $21.76 billion. Recent institutional ratings show a generally positive bias, with several firms maintaining or upgrading to 'Buy' or 'Overweight' ratings in early 2026, including actions from TD Cowen and Barclays. A specific consensus target price is not provided in the data.
Bulls vs Bears: IQV Investment Factors
IQVIA presents a classic growth-at-a-reasonable-price versus high-risk profile. Strong fundamentals in revenue growth, cash flow, and profitability are offset by significant leverage, recent severe price weakness, and valuation concerns. The stock is at a critical juncture, trading near 52-week lows despite solid underlying business performance.
Bullish
- Strong Revenue and Earnings Growth: Q4 revenue grew 10.3% YoY. Net income surged 55% QoQ to $514M.
- Robust Free Cash Flow: TTM free cash flow of $2.48B provides financial flexibility and supports deleveraging.
- High Return on Equity: ROE of 20.9% indicates efficient use of shareholder capital.
- Attractive Forward P/E: Forward P/E of 12.1 is reasonable, suggesting earnings growth is priced in.
Bearish
- High Debt and Weak Liquidity: Debt-to-equity of 2.49 is high. Current ratio of 0.75 signals liquidity risk.
- Significant Price Downtrend: Stock down 24% over 3 months and 31% from its 52-week high.
- Expensive PEG Ratio: PEG ratio of 6.34 suggests the stock is pricey relative to its growth rate.
- Market Underperformance: Severe negative relative strength vs. S&P 500 over 3-month (-19.7) and YTD (-19.7) periods.
IQV Technical Analysis
The stock has experienced significant volatility and a pronounced downtrend over the past six months. From a closing price of $204.34 on October 2, 2025, it declined to $170.54 by March 31, 2026, representing a 6-month decline of 16.5%. The price peaked at $247.05 within the provided data period before a sharp correction. Short-term performance has been weak, with the stock down 24.3% over the last three months and 4.6% over the past month. This underperformance is stark compared to the broader market, as indicated by relative strength figures of -19.7 (3-month) and 0.6 (1-month). The decline accelerated notably in early February 2026. The current price of $170.54 sits near the lower end of its 52-week range of $134.65 to $247.05, representing a recovery from the low $160s seen in late February and March but still significantly below the high. The stock is currently trading 31% below its 52-week high.
Beta
1.39
1.39x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$135-$247
Price range past year
Annual Return
-0.6%
Cumulative gain past year
| Period | IQV Return | S&P 500 |
|---|---|---|
| 1m | -0.4% | -3.6% |
| 3m | -23.1% | -4.0% |
| 6m | -16.1% | -2.0% |
| 1y | -0.6% | +16.2% |
| ytd | -23.1% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IQV Fundamental Analysis
Revenue growth has been positive, with Q4 2025 revenue of $4.36 billion representing a 10.3% year-over-year increase from Q4 2024. Quarterly sequential revenue also grew from $4.10 billion in Q3 2025. Profitability metrics show a net margin of 11.8% for Q4 2025, a significant improvement from the 8.1% net margin in Q3 2025, driven by a substantial increase in net income to $514 million from $331 million the prior quarter. Financial health is a mixed picture. The company carries a high debt-to-equity ratio of 2.49, indicating significant leverage. However, it maintains a strong trailing twelve-month free cash flow of $2.48 billion, and operating cash flow for Q4 2025 was a healthy $735 million. The current ratio is 0.75, which suggests potential liquidity constraints in covering short-term obligations. Operational efficiency is solid, with a Return on Equity (ROE) of 20.9% and a Return on Assets (ROA) of 5.05%. The company's asset turnover and operational margins have shown improvement in the most recent quarter, with operating income reaching $732 million in Q4 2025.
Quarterly Revenue
$4.4B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IQV Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 28.5, while the forward P/E is lower at 12.1, based on estimated future earnings. The Price-to-Sales (P/S) ratio is 2.38, and the Enterprise Value-to-Sales (EV/Sales) is 2.65. Peer comparison data is not available in the provided inputs. The valuation appears to be factoring in future growth expectations, as the forward P/E is substantially lower than the trailing P/E, suggesting analysts anticipate significant earnings growth. The PEG ratio of 6.34, however, indicates the stock may be priced expensively relative to its expected growth rate.
PE
28.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
IQVIA's primary risk is its financial leverage, with a debt-to-equity ratio of 2.49, which could strain the balance sheet in a rising interest rate environment or an economic downturn. The low current ratio of 0.75 indicates potential difficulty in meeting short-term obligations without refinancing or tapping its strong cash flow. Market-related risks are pronounced, as evidenced by the stock's 33.7% maximum drawdown and severe underperformance relative to the broader market, suggesting investor sentiment has turned negative, possibly due to sector-wide concerns or growth fears. Operational risks include volatile gross margins, which plummeted in the last quarter, and the high PEG ratio of 6.34, indicating the market has priced in aggressive growth that may not materialize, leaving the stock vulnerable to earnings disappointments.
FAQ
The key risks are financial and market-related. Financially, the high debt-to-equity ratio of 2.49 and a weak current ratio of 0.75 pose liquidity and refinancing risks. Market-wise, the stock has shown extreme volatility with a 33.7% drawdown and severe underperformance versus the S&P 500. There is also operational risk from fluctuating gross margins, which dropped sharply last quarter.
The 12-month outlook is for a potential recovery with a base case target range of $185 to $215 (55% probability), implying an 8-26% upside from $170.54. This assumes the company meets analyst EPS estimates of ~$19.50. A bullish case to $247 (25% probability) requires multiple expansion and debt reduction, while a bearish case could see a retest of lows near $135 (20% probability) if growth disappoints.
IQV's valuation sends mixed signals. It appears reasonably valued on a forward earnings basis with a P/E of 12.1, but expensive on a growth-adjusted basis with a PEG ratio of 6.34. The trailing P/E of 28.5 is high, reflecting past earnings compression. Given the recent sharp price decline to $170.54, the stock is likely fairly valued to slightly undervalued if it can hit future EPS estimates of $19.50, but carries significant execution risk.
IQV is a Hold, not a clear Buy at this moment. The company has excellent fundamentals like 10.3% revenue growth and strong cash flow, but these are overshadowed by high debt (D/E of 2.49) and a stock price that has fallen 31% from its high. The forward P/E of 12.1 is attractive, but investors should wait for price stabilization or debt reduction progress before committing new capital.
IQV is suitable only for long-term investors with a higher risk tolerance. The significant debt load and recent price volatility make it unsuitable for short-term trading. Long-term investors can potentially benefit from the company's entrenched market position and growth in healthcare data analytics, but they must be prepared for a potentially rocky journey as the company manages its balance sheet and the stock rebuilds investor confidence.